VivoSim Labs, Inc. (VIVS)
US — Healthcare Sector
Peers:
Automate Your Wheel Strategy on VIVS
With Tiblio's Option Bot, you can configure your own wheel strategy including VIVS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VIVS
- Rev/Share 0.1022
- Book/Share 7.4478
- PB 0.2544
- Debt/Equity 0.0898
- CurrentRatio 3.2462
- ROIC -1.1043
- MktCap 4926621.0
- FreeCF/Share -6.7251
- PFCF -0.52
- PE -1.073
- Debt/Assets 0.0643
- DivYield 0
- ROE -0.4695
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About VivoSim Labs, Inc. (VIVS)
- IPO Date 2012-02-14
- Website https://www.organovo.com
- Industry Biotechnology
- CEO Keith E. Murphy
- Employees 14
VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. The company was incorporated in 2007 and is headquartered in San Diego, California.